⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025

Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study assesses the efficacy of zilovertamab vedotin in participants with metastatic solid tumors.
The study population evaluation reveals critical insights into participant representativeness in a phase 2 context.
This phase 2 study methodology focuses on detailed participant demographic assessment and treatment outcomes.
Understanding participant representativeness is crucial for evaluating treatment efficacy and generalizability.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase 2 study evaluates zilovertamab vedotin effects on metastatic solid tumors, highlighting participant representativeness.

Abstract

Supplemental Table S2. Representativeness of the Study Population

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61b09 https://doi.org/10.1158/2767-9764.30146493

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Table S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025